12:00 AM
Nov 22, 1999
 |  BC Week In Review  |  Clinical News  |  Regulatory

TP20 combination of soluble complement receptor 1 regulatory update

AVAN received U.S. Patent No. 5,976,540 covering use of the company's TP20 complement/selectin...

Read the full 44 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >